Display options
Cite
Bieniek A, Wiśniewski M, Czarnecka J, et al. Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment. Int J Mol Sci. 2021;22(20)doi: 10.3390/ijms222011161.
Bieniek, A., Wiśniewski, M., Czarnecka, J., Wierzbicki, J., Ziętek, M., Nowacki, M., Grzanka, D., Kloskowski, T., & Roszek, K. (2021). Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment. International journal of molecular sciences, 22(20), . https://doi.org/10.3390/ijms222011161
Bieniek, Adam, et al. "Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment." International journal of molecular sciences vol. 22,20 (2021). doi: https://doi.org/10.3390/ijms222011161
Bieniek A, Wiśniewski M, Czarnecka J, Wierzbicki J, Ziętek M, Nowacki M, Grzanka D, Kloskowski T, Roszek K. Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment. Int J Mol Sci. 2021 Oct 16;22(20). doi: 10.3390/ijms222011161. PMID: 34681820; PMCID: PMC8536990.
Copy Download .nbib Format: NLM
Share it on

Int J Mol Sci. 2021 Oct 16;22(20). doi: 10.3390/ijms222011161.

Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment.

International journal of molecular sciences

Adam Bieniek, Marek Wiśniewski, Joanna Czarnecka, Jędrzej Wierzbicki, Marcin Ziętek, Maciej Nowacki, Dariusz Grzanka, Tomasz Kloskowski, Katarzyna Roszek

Affiliations

  1. Physicochemistry of Carbon Materials Research Group, Faculty of Chemistry, Nicolaus Copernicus University in Toru?, 87-100 Toru?, Poland.
  2. Department of Biochemistry, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University in Toru?, 87-100 Toru?, Poland.
  3. Student's Scientific Society, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Jagiello?ska Street 13/15, 85-067 Bydgoszcz, Poland.
  4. Department of Oncology, Wroclaw Medical University, 53-413 Wroclaw, Poland.
  5. Lower Silesian Comprehensive Cancer Center, Department of Surgical Oncology, Hirszfelda 12, 53-413 Wroclaw, Poland.
  6. Department of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Ludwik Rydygier Medical College in Bydgoszcz, Nicolaus Copernicus University in Torun, Sklodowskiej-Curie 9 Street, 85-094 Bydgoszcz, Poland.
  7. Department of Pathology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Sklodowskiej-Curie 9 Street, 85-094 Bydgoszcz, Poland.
  8. Department of Regenerative Medicine, Cell and Tissue Bank, Nicolaus Copernicus University in Torun, Ludwik Rydygier Medical College in Bydgoszcz, 85-094 Bydgoszcz, Poland.

PMID: 34681820 PMCID: PMC8536990 DOI: 10.3390/ijms222011161

Abstract

The existing clinical protocols of hepatoma treatment require improvement of drug efficacy that can be achieved by harnessing nanomedicine. Porphyrin-based, paddle-wheel framework (PPF) structures were obtained and tested as dual-kinetic Sorafenib (SOR) nanocarriers against hepatoma. We experimentally proved that sloughing of PPF structures combined with gradual dissolving are effective mechanisms for releasing the drug from the nanocarrier. By controlling the PPF degradation and size of adsorbed SOR deposits, we were able to augment SOR anticancer effects, both in vitro and in vivo, due to the dual kinetic behavior of SOR@PPF. Obtained drug delivery systems with slow and fast release of SOR influenced effectively, although in a different way, the cancer cells proliferation (reflected with EC50 and ERK 1/2 phosphorylation level). The in vivo studies proved that fast-released SOR@PPF reduces the tumor size considerably, while the slow-released SOR@PPF much better prevents from lymph nodes involvement and distant metastases.

Keywords: 2D metal–organic framework; PPF structure; anticancer drug delivery; multikinase inhibitors; sorafenib

References

  1. Langmuir. 2010 Nov 16;26(22):17198-202 - PubMed
  2. ACS Appl Mater Interfaces. 2019 Nov 27;11(47):43996-44006 - PubMed
  3. Dalton Trans. 2016 Mar 7;45(9):3668-78 - PubMed
  4. Cancer Res. 2006 Dec 15;66(24):11851-8 - PubMed
  5. Adv Mater. 2015 Dec 2;27(45):7372-8 - PubMed
  6. J Basic Clin Pharm. 2016 Mar;7(2):27-31 - PubMed
  7. Nat Commun. 2014;5:2995 - PubMed
  8. Nat Mater. 2010 Jul;9(7):565-71 - PubMed
  9. Nat Chem. 2009 Dec;1(9):695-704 - PubMed
  10. PLoS One. 2016 May 12;11(5):e0155001 - PubMed
  11. Mol Cancer Ther. 2011 Jun;10(6):1007-17 - PubMed
  12. Acta Pharmacol Sin. 2020 Dec;41(12):1609-1620 - PubMed
  13. J Mater Chem B. 2018 Dec 21;6(47):7898-7907 - PubMed
  14. Science. 2014 Dec 12;346(6215):1356-9 - PubMed
  15. ACS Nano. 2019 Aug 27;13(8):9206-9217 - PubMed
  16. Cell Cycle. 2012 Aug 1;11(15):2843-55 - PubMed
  17. Small. 2017 May;13(17): - PubMed
  18. Theranostics. 2021 Mar 13;11(11):5464-5490 - PubMed
  19. Cancers (Basel). 2020 May 26;12(6): - PubMed
  20. J Colloid Interface Sci. 2013 Feb 1;391:74-85 - PubMed
  21. Adv Mater. 2015 Oct 7;27(37):5605-9 - PubMed
  22. Angew Chem Int Ed Engl. 2021 Mar 1;60(10):5010-5035 - PubMed
  23. Langmuir. 2005 Dec 20;21(26):12257-67 - PubMed
  24. Chem Soc Rev. 2021 May 7;50(9):5706-5745 - PubMed
  25. Chem Soc Rev. 2018 Mar 21;47(6):2130-2144 - PubMed
  26. Expert Opin Pharmacother. 2016 Oct;17(14):1923-36 - PubMed
  27. Oncotarget. 2017 Nov 6;8(63):107096-107108 - PubMed
  28. Theranostics. 2012;2(9):905-15 - PubMed
  29. Molecules. 2020 Feb 11;25(4): - PubMed
  30. J Hepatol. 2007 May;46(5):840-8 - PubMed

Publication Types

Grant support